Acylguanidines as Bioisosteres of Guanidines: NG-Acylated Imidazolylpropylguanidines, a New Class of Histamine H2 Receptor Agonists

被引:64
作者
Ghorai, Prasanta [1 ]
Kraus, Anja [1 ]
Keller, Max [1 ]
Goette, Carsten [1 ]
Igel, Patrick [1 ]
Schneider, Erich [2 ]
Schnell, David [2 ]
Bernhardt, Guenther [1 ]
Dove, Stefan [1 ]
Zabel, Manfred [3 ]
Elz, Sigurd [1 ]
Seifert, Roland [2 ]
Buschauer, Armin [1 ]
机构
[1] Univ Regensburg, Fac Chem & Pharm, Dept Pharmaceut Med Chem, Inst Pharm, D-93053 Regensburg, Germany
[2] Univ Regensburg, Fac Chem & Pharm, Dept Pharmacol & Toxicol, Inst Pharm, D-93053 Regensburg, Germany
[3] Univ Regensburg, Fac Chem & Pharm, Ctr Chem Anal, Xray Lab, D-93053 Regensburg, Germany
关键词
D O I
10.1021/jm800841w
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
N-1-Aryl(heteroaryl)alkyl-N-2-[3-(1H-imidazol-4-yl)propyl]guanidines are potent histamine H-2-receptor (H2R) agonists, but their applicability is compromised by the lack of oral bioavailability and CNS penetration. To improve pharmacokinetics, we introduced carbonyl instead of methylene adjacent to the guanidine moiety, decreasing the basicity of the novel H2R agonists by 4-5 orders of magnitude. Some acylguanidines with one phenyl ring were even more potent than their diaryl analogues. As demonstrated by HPLC-MS, the acylguanidines (bioisosteres of the alkylguanidines) were absorbed from the gut of mice and detected in brain. In GTPase assays using recombinant receptors, acylguanidines were more potent at the guinea pig than at the human H2R. At the hH(1)R and hH(3)R, the compounds were weak to moderate antagonists or partial agonists. Moreover, potent partial hH(4)R agonists were identified. Receptor subtype selectivity depends on the imidazolylpropylguanidine moiety (privileged structure), opening an avenue to distinct pharmacological tools including potent H4R agonists.
引用
收藏
页码:7193 / 7204
页数:12
相关论文
共 60 条
[1]   AUTO-INHIBITION OF BRAIN HISTAMINE-RELEASE MEDIATED BY A NOVEL CLASS (H-3) OF HISTAMINE-RECEPTOR [J].
ARRANG, JM ;
GARBARG, M ;
SCHWARTZ, JC .
NATURE, 1983, 302 (5911) :832-837
[2]   AUTOINHIBITION OF HISTAMINE SYNTHESIS MEDIATED BY PRESYNAPTIC H-3 RECEPTORS [J].
ARRANG, JM ;
GARBARG, M ;
SCHWARTZ, JC .
NEUROSCIENCE, 1987, 23 (01) :149-157
[3]   SOME QUANTITATIVE USES OF DRUG ANTAGONISTS [J].
ARUNLAKSHANA, O ;
SCHILD, HO .
BRITISH JOURNAL OF PHARMACOLOGY AND CHEMOTHERAPY, 1959, 14 (01) :48-58
[4]  
Ballasteros J. A., 1995, Methods in neurosciences, V25, P366
[5]   POSSIBLE VALUE OF H-2-RECEPTOR AGONISTS FOR TREATMENT OF CATECHOLAMINE-INSENSITIVE CONGESTIVE HEART-FAILURE [J].
BAUMANN, G ;
PERMANETTER, B ;
WIRTZFELD, A .
PHARMACOLOGY & THERAPEUTICS, 1984, 24 (02) :165-177
[6]  
BAUMANN G, 1984, INFLAMM RES, V15, P216
[7]   DEFINITION AND ANTAGONISM OF HISTAMINE H2-RECEPTORS [J].
BLACK, JW ;
PARSONS, EM ;
DURANT, CJ ;
DUNCAN, WAM ;
GANELLIN, CR .
NATURE, 1972, 236 (5347) :385-&
[8]  
Brennauer A, 2004, HANDB EXP PHARM, V162, P505
[9]  
Brennauer A., 2006, THESIS U REGENSBURG
[10]   HISTAMINE INHIBITS ACTIVATION OF HUMAN-NEUTROPHILS AND HL-60 LEUKEMIC-CELLS VIA H-2-RECEPTORS [J].
BURDE, R ;
SEIFERT, R ;
BUSCHAUER, A ;
SCHULTZ, G .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1989, 340 (06) :671-678